Feedback
Settings

Settings

Goto Application

744,670 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 74,467
1.WO/2026/102027COMPOSITIONS TARGETING AU-RICH ELEMENTS OF FGF21 GENE AND GDF15 GENE AND METHODS OF USE THEREOF
WO - 15.05.2026
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No PCT/US2025/054202 Applicant POSEIDA THERAPEUTICS, INC. Inventor SCHWERK, Johannes
gene. This disclosure further provides compositions and methods for genomic editing of AU-rich elements in the FGF21 and/or GDF15 genes for treating obesity-related diseases and disorders.
2.WO/2026/102237ARTIFICIAL EXPRESSION CONSTRUCTS FOR MODULATING GENE EXPRESSION IN ASTROCYTES FOR THE ASSESSMENT AND/OR TREATMENT OF EPILEPTIC DISORDERS
WO - 15.05.2026
Int.Class C12N 15/864
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
864Parvoviral vectors
 Appl.No PCT/US2025/054539 Applicant ALLEN INSTITUTE Inventor GORE, Bryan
Artificial expression constructs for modulating gene expression in targeted central nervous system cell types are described. The artificial expression constructs can be used in the assessment and/or treatment of epileptic disorders.
3.WO/2026/102252COMPOSITION AND METHOD FOR MODULATING MICROBIOMES WITH POSTBIOTIC FERMENTS
WO - 15.05.2026
Int.Class C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
 Appl.No PCT/US2025/054563 Applicant KIMBERLY-CLARK WORLDWIDE, INC. Inventor QUIRK, Stephen
spp. bacteria to prevent dysbiosis and other related conditions and infections.
4.WO/2026/102372GENOMIC DNA AMPLIFICATION AND BARCODING
WO - 15.05.2026
Int.Class C12Q 1/6855
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6844Nucleic acid amplification reactions
6853using modified primers or templates
6855Ligating adaptors
 Appl.No PCT/US2025/054759 Applicant ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY Inventor GEILER-SAMEROTTE, Kerry
. In the first step of amplification, primers are employed that that bind a target sequence; and post-amplification, a barcoded primer is ligated onto the newly amplified double-stranded DNA, the barcoded primer having a free end that allows the attachment of additional barcodes. This strategy provides for improved amplification efficiency over methods previously used in the art.
5.WO/2026/102462ENGINEERED CELLS FOR TREATING DIABETES
WO - 15.05.2026
Int.Class A61K 35/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
48Reproductive organs
54Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
545Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
 Appl.No PCT/US2025/055010 Applicant CITY OF HOPE Inventor YEE, Jiing-Kuan
, genetically engineered human pluripotent stem cells, beta cells derived from genetically engineered human pluripotent stem cells, compositions, and cell aggregates, and methods of treating diabetes. The human pluripotent stem cells and beta cells provided herein including embodiments thereof may be genetically modified to express exogenous genes and/or inactivate endogenous genes.
6.WO/2026/099477DOSING OF OLIGONUCLEOTIDE DRUGS FOR INHALATION
WO - 15.05.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/EP2025/082448 Applicant RNATICS GMBH Inventor RABE, Klaus F.
The present invention relates to a formulation comprising an oligonucleotide drug which is an antagonist of microRNA-21 as an active agent for administration to a human subject in need thereof by inhalation.
7.WO/2026/099582CONSTRUCTS FOR RNA EXPRESSION
WO - 15.05.2026
Int.Class C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
 Appl.No PCT/GB2025/052425 Applicant OXFORD UNIVERSITY INNOVATION LIMITED Inventor HUGHES, James, Raymond
Provided are synthetic constructs for providing an enhancer or variant thereof as a promoter to drive RNA expression, as well as nucleic acids, vectors, and cells encoding or comprising said constructs. Associated methods and pharmaceutical compositions for use in therapy are also provided herein.
8.WO/2026/099807TYPE-I INTERFERON RESPONSE AND EXHAUSTION GENE SIGNATURE AS A BIOMARKER FOR CANCER IMMUNOTHERAPY
WO - 15.05.2026
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
 Appl.No PCT/IB2025/061397 Applicant UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor FERRIS, Robert, Louis
Provided herein is a method of treating a patient having a tumor, including determining whether one or more immune cells from the patient express an exhaustion phenotype and administering to the patient one or more therapeutic compositions, wherein: the therapeutic composition includes either one or more checkpoint inhibitors (ICIs) in an amount effective to treat the tumor when the one or more immune cells express the exhaustion phenotype or one or more compounds effective to prime the one or more immune cells to respond to one or more ICIs when the one or more cells do not express the exhaustion phenotype.
9.WO/2026/098802ULK1 INHIBITOR FOR THE TREATMENT OF A NEURODEGENERATIVE DISEASE
WO - 15.05.2026
Int.Class A61K 31/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
 Appl.No PCT/EP2025/070130 Applicant ETH ZÜRICH Inventor GEREZ, Juan Atilio
The invention relates to a ULK1 inhibitor for use in the treatment of a human or mammalian patient being diagnosed for, suffering from, or being at risk of developing a neurodegenerative disease, or in the prevention of such condition.
10.WO/2026/097827SWARMING-MOTILITY ENTEROBACTER LUDWIGII AND USE THEREOF
WO - 15.05.2026
Int.Class C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
 Appl.No PCT/CN2025/096776 Applicant SHANGHAI LISHAN BIOPHARMACEUTICAL CO., LTD. Inventor CHEN, Weijie
Provided are an Enterobacter ludwigii strain and use thereof in the amelioration of inflammatory bowel disease. The present invention belongs to the technical field of new applications of microorganisms. The strain is named Enterobacter ludwigii LS-57 and is deposited in China General Microbiological Culture Collection Center under the accession number CGMCC NO. 31424, with a deposit date of July 22, 2024. The strain exhibits swarming motility, has relatively strong adaptability to the intestinal environment, tolerates gastric juice acidity well, is sensitive to various commonly used antibiotics, and has a good ameliorative effect on colitis.
# -